Drug Trial Radar · NCT07492628
Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Mar 2, 2026
Primary completion
Jun 14, 2027
Study completion May 17, 2028
Sponsor
- Lead sponsor
- Beijing BiotechIndustry
- Sponsor type
- Industry
- First posted
- Mar 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is first-in-human study is designed to evaluate the safety, feasibility, and preliminary anti-tumor activity of an allogeneic dual-target Nectin-4/HER2 CAR-NK cell product in adults with relapsed/refractory locally advanced or metastatic urothelial carcinoma. Based on public urothelial-cancer evidence, Nectin-4 was selected as the lead antigen because it has the strongest disease-specific clinical validation; HER2/ERBB2 was chosen as the secondary co-target to broaden tumor coverage and reduce antigen-escape risk. EpCAM is not selected as a therapeutic co-target in this example because of broader normal epithelial expression and weaker tumor specificity in urothelial carcinoma.
Conditions
- Bladder Cancer
- Urothelial Carcinoma
- Metastatic Urothelial Carcinoma
- Locally Advanced Urothelial Carcinoma
- Upper Tract Urothelial Carcinoma
Interventions
EB-DT-NK-UC101Biological
Allogeneic cord-blood-derived dual-target Nectin-4/HER2 CAR-NK cells with inducible caspase-9 safety switch.
CyclophosphamideDrug
Lymphodepleting chemotherapy given before the first CAR-NK infusion.
FludarabineDrug
Lymphodepleting chemotherapy given before the first CAR-NK infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs)Time frame: 28 Days
- Incidence and severity of treatment-emergent adverseTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.